Search
Displaying all 2 results
Daraxonrasib
go.drugbank.com/drugs/DB22308
ApprovedInvestigational
Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS a...
Pancreatic Adenocarcinoma Metastatic
go.drugbank.com/conditions/DBCOND0060224